 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
| Company type | Public |
|---|---|
| OTCQB: ENUM | |
| Industry | Biotechnology |
| Founded | December 11, 2009 |
| Defunct | January 29, 2018 |
| Fate | Assets sold to Xoma Corporation during bankruptcy |
| Headquarters | , United States |
Key people | |
| Products | Monoclonal antibodies targeting immune checkpoint proteins |
Number of employees | 10 (2017)[3] |
| Website | www |
Enumeral was a Cambridge, Massachusetts-based biotechnology company which developed monoclonal antibody immunotherapies through an 'immunoprofiling' platform that allowed it to scan the human immune microenvironment and identify and validate potential drug candidates. The company filed for Chapter 11 bankruptcy and arranged to sell its assets to Xoma Corporation in January 2018.
- ^ Cite error: The named reference
keown2018biospacewas invoked but never defined (see the help page). - ^ Cite error: The named reference
sec8kJan2018was invoked but never defined (see the help page). - ^ Cite error: The named reference
keown2017biospacewas invoked but never defined (see the help page).
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search